[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Travere Therapeutics director Roy D. Baynes reported an options exercise and share sale. On the same date, he exercised stock options to acquire 4,500 shares of common stock at $21.38 per share and sold 4,500 shares in an open-market transaction at $50.00 per share.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, Baynes directly holds 41,500 shares of Travere Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,500 shares ($225,000)
Net Sell
3 txns
Insider
Baynes Roy D.
Role
Director
Sold
4,500 shs ($225K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 4,500 | $0.00 | -- |
| Exercise | Common Stock | 4,500 | $21.38 | $96K |
| Sale | Common Stock | 4,500 | $50.00 | $225K |
Holdings After Transaction:
Stock option (right to buy) — 0 shares (Direct);
Common Stock — 46,000 shares (Direct)
Footnotes (1)
- This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. The stock option is fully vested and exercisable.
Key Figures
Shares sold: 4,500 shares
Sale price: $50.00 per share
Options exercised: 4,500 shares
+3 more
6 metrics
Shares sold
4,500 shares
Common stock sold in open-market transaction at $50.00 per share
Sale price
$50.00 per share
Price for 4,500 Travere common shares sold
Options exercised
4,500 shares
Common shares acquired via stock option exercise
Exercise price
$21.38 per share
Exercise price for stock option covering 4,500 shares
Post-transaction holdings
41,500 shares
Travere common shares directly owned after transactions
Rule 10b5-1 plan adoption date
November 17, 2025
Date written trading plan governing the sale was adopted
Key Terms
Rule 10b5-1(c), stock option, open-market sale, derivative security
4 terms
Rule 10b5-1(c) regulatory
"plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
stock option financial
"consists of the sale of shares underlying stock options granted to the Reporting Person"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
